Results showed antagonists of AQP1, Na+, K+, and Ca2+ channels; Ca2+-activated K+ channels; and AMPA/kainate-type glutamate receptors, and an agonist of metabotropic glutamate receptors, are promising targets for the optimization of small-molecule inhibitors of glioblastoma tumor motility. Here, AQP1 is linked to neoplasm.